New drug LG-0317 enters first human safety trial
NCT ID NCT07522970
First seen May 01, 2026 · Last updated Jun 19, 2026 · Updated 10 times
Summary
This early-stage study is testing LG-0317 tablets for the first time in people. About 100 healthy Chinese adults aged 18-45 will receive either the drug or a placebo to check for side effects and how the body processes it. The goal is to see if the drug is safe enough to move into future studies for potential diseases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Xuhui Central Hospital
RECRUITINGShanghai, Shanghai Municipality, 200237, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LG-0317
What could go wrong
This is a very early phase 1 trial in healthy volunteers, so it cannot show any treatment benefit. The drug may prove unsafe or ineffective in later studies.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.